Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.20815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs).
BMC Cancer
October 2024
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Article Synopsis
- Effective management of skin rash, a common side effect of imatinib in GIST treatment, can be achieved with systemic steroids, which allow for the continuation of imatinib dosing without interruptions.
- A study involving 277 patients found that 30 (10.8%) required systemic steroids for severe skin rash, but there was no significant difference in progression-free survival (PFS) or overall survival (OS) between those using steroids and those who did not.
- Results showed that while the steroids didn't impact the overall effectiveness of imatinib, patients in the steroid group who maintained their imatinib dosage had improved survival trends compared to those who had dosage interruptions.
Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor.
Int Immunopharmacol
October 2024
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan 430022, China. Electronic address:
Imatinib-induced skin rash poses a significant challenge for patients with gastrointestinal stromal tumor, often resulting in treatment interruption or discontinuation and subsequent treatment failure. However, the underlying mechanism of imatinib-induced skin rashes in gastrointestinal stromal tumor patients remains unclear. A total of 51 patients (27 with rash and 24 without rash) were enrolled in our study.
View Article and Find Full Text PDF[IMATINIB INDUCED EDEMA].
Harefuah
June 2024
Department of Medicine E, Sheba Medical Center Tel-Hashomer, affiliated to Faculty of Medicine, Tel-Aviv University Israel.
Imatinib is a tyrosine kinase inhibitor and is used for the treatment of chronic myeloid leukemia (CML) since 2002. We present a patient who suffered from fluid retention and periorbital edema secondary to this drug.
View Article and Find Full Text PDFImatinib-induced ulcerative colitis.
J Oncol Pharm Pract
September 2024
Department of Respiratory, Nanjing Gaochun People's Hospital, Nanjing, China.
Introduction: Imatinib, a tyrosine kinase inhibitor, is the first-line therapy for patients with KIT mutation in gastrointestinal stromal tumor (GIST). Nausea, vomiting, diarrhea, dyspepsia and abdominal pain are common gastrointestinal adverse reactions of imatinib, but imatinib-induced ulcerative colitis (UC) is rarely reported.
Case Report: We presented a case of UC induced by imatinib in a 56-year-old male patient who experienced this adverse event after 5 years of imatinib 400 mg/d treatment following GIST resection.
Imatinib-induced dermatomyositis - a rare case report.
Front Immunol
May 2024
Rheumatology Department, EULAR Centre of Excellence, Unidade Local de Saúde Santa Maria, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
Idiopathic Inflammatory Myopathies are rare conditions with several heterogeneous disease subtypes. They can range from limited muscle or skin involvement to severe, systemic, life-threatening disease. Although the etiology is unknown, some evidence suggests a role for external agents, particularly drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!